In vitro pharmacodynamic modelling of anidulafungin against Candida spp

Int J Antimicrob Agents. 2016 Mar;47(3):178-83. doi: 10.1016/j.ijantimicag.2015.12.011. Epub 2016 Jan 15.

Abstract

The aim of this study was to fit anidulafungin in vitro static time-kill data from nine strains of Candida with a pharmacodynamic (PD) model in order to describe the antifungal activity of this drug against Candida spp. Time-kill data from strains of Candida albicans, Candida glabrata and Candida parapsilosis clades were best fit using an adapted sigmoidal Emax model and resulted in a set of PD parameters (Emax, EC50 and Hill factor) for each fungal strain. The data were analysed with NONMEM 7. Anidulafungin was effective in a species- and concentration-dependent manner against the strains of C. glabrata and C. parapsilosis clades as observed with the EC50 estimates. Maximum killing rate constant (Emax) values were higher against C. glabrata and C. parapsilosis complex strains. In conclusion, we demonstrated that the activity of anidulafungin against Candida can be accurately described using an adapted sigmoidal Emax model.

Keywords: Anidulafungin; Candida; In vitro; Modelling; Pharmacodynamic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anidulafungin
  • Antifungal Agents / pharmacology*
  • Candida albicans / drug effects*
  • Candida glabrata / drug effects*
  • Candidiasis / drug therapy
  • Echinocandins / pharmacology*
  • Humans
  • Microbial Sensitivity Tests
  • Models, Statistical

Substances

  • Antifungal Agents
  • Echinocandins
  • Anidulafungin